Kadja Luana Chagas Monteiro

Kadja Luana Chagas Monteiro

Auto-generated profile, based on publicly available information

Kadja Luana Chagas Monteiro

Research Group on Therapeutic Strategies - GPET, Laboratory of Synthesis and Research in Medicinal Chemistry - LSPMED, Institute of Chemistry and Biotechnology, Federal University of Alagoas, 57072-970, Maceió, Alagoas, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
KMKadja Luana Chagas Monteiro
Kadja Luana Chagas Monteiro
MAMarcone Gomes dos Santos Alcântara
Marcone Gomes dos Santos Alcântara
TAThiago Aquino
Thiago Aquino
Edeíldo Ferreira da Silva-JúniorEdeíldo Ferreira da Silva-Júnior
Edeíldo Ferreira da Silva-Júnior
: Major research in Alzheimer’s disease (AD) related to disease-modifying agents is concentrated on pharmacological approaches related to diagnostic markers, neurofibrillary tangles and amyloid plaques. Although most studies focus on anti-amyloid strategies, investigations on tau protein have produced significant advances in the modulation of the pathophysiology of several neurodegenerative diseases. Since the discovery of phenothiazines as tau protein aggregation inhibitors (TAGIs), many additional small molecule inhibitors have been discovered and characterized in biological model systems, which exert their interaction effects by covalent and noncovalent means. In this paper, we summarize the latest advances in the discovery and development of tau aggregation inhibitors using a specialized approach in their chemical classes. The design of new TAGIs and their encouraging use in in vivo and clinical trials support their potential therapeutic use in AD.

1 September 2022 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
KMKadja Luana Chagas Monteiro
Kadja Luana Chagas Monteiro
OSOsmar Nascimento Silva
Osmar Nascimento Silva
Igor José dos Santos NascimentoIgor José dos Santos Nascimento
Igor José dos Santos Nascimento
Francisco Mendonça JuniorFrancisco Mendonça Junior
Francisco Mendonça Junior
PAPedro Aquino
Pedro Aquino
TAThiago Aquino
Thiago Aquino
The discovery of antibiotics was a revolutionary feat that provided countless health bene-fits. The identification of penicillin by Alexander Fleming initiated the era of antibiotics, represent-ed by constant discoveries that enabled effective treatments for the different classes of diseases caused by bacteria. However, the indiscriminate use of these drugs allowed the emergence of re-sistance mechanisms of these microorganisms against the available drugs. In addition, the constant discoveries in the 20th century generated a shortage of new molecules, worrying health agencies and professionals about the appearance of multidrug-resistant strains against available drugs. In this context, the advances of recent years in molecular biology and microbiology have allowed new per-spectives in drug design and development, using the findings related to the mechanisms of bacterial resistance to generate new drugs that are not affected by such mechanisms and supply new mole-cules to be used to treat resistant bacterial infections. Besides, a promising strategy against bacterial resistance is the combination of drugs through adjuvants, providing new expectations in designing new antibiotics and new antimicrobial therapies. Thus, this manuscript will address the main mech-anisms of bacterial resistance under the understanding of medicinal chemistry, showing the main active compounds against efflux mechanisms, and also the application of the use of drug delivery systems, and finally, the main potential natural products as adjuvants or with promising activity against resistant strains.